Arkema: Disclosure of Trading in Own Shares from 26 May to 26 May 2025
LA DÉFENSE, France, June 04, 2025--(BUSINESS WIRE)--Regulatory News:
In accordance with applicable regulations, Arkema (Paris:AKE) announces having carried out the following share buyback transactions in accordance with Article 5 §2 of Regulation (EU) No 596/2014 from 26 May to 26 May 2025
Name of the issuer
Issuer identifier code
Day of the transaction
Financial instrument identifier code
Total daily volume (number of shares)
Weighted average price of daily acquisition
Market identifier code
ARKEMA
9695000EHMS84KKP2785
5/26/2025
FR0010313833
1698
63.3006
XPAR
TOTAL
1,698
63.3006
Detailed information can be found on the Group Arkema website: https://www.arkema.com/en/investor-relations/arkema-share/share-buybacks/2025/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604267137/en/
Contacts
Arkema
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
When does transfer window close? Liverpool's deadline for signing Florian Wirtz
Liverpool is looking to get its business done early on in the transfer window, with Jeremie Frimpong already through the door and prodigious Hungarian goalkeeper Armin Pecsi joining him on Saturday. Pecsi, 20, has been signed for a fee that could rise to $2 million and is expected to play for Liverpool's Under-21 team next term, while also benefiting from training alongside Alisson and Giorgi Mamardashvili. Advertisement The signing that the majority of Liverpool fans are most excited about, though, is that of Florian Wirtz, who is expected to secure a move to Anfield from Bayer Leverkusen. It emerged last month that Wirtz had decided he wanted to join Liverpool over Bayern Munich, and the Reds have been working to try to get a deal over the line in recent weeks. READ MORE: Liverpool transfer news LIVE: Florian Wirtz medical, next signing imminent, Milos Kerkez latest READ MORE: Liverpool sent Jack Grealish message as big summer continues to take shape When does the transfer window close? Liverpool is hopeful of tying up a deal for Wirtz before the first transfer window of the summer closes on Tuesday, June 10, but even if the deal is not done by then, the second window of the summer opens less than a week later and runs until the beginning of September, so the Reds will not panic if Wirtz's signature hasn't been secured by June 10. Advertisement The new transfer window that opened on June 1 was introduced so that clubs participating in this summer's revamped Club World Cup could make signings ahead of the tournament getting underway in mid-June. Liverpool made an improved bid to sign Wirtz from Bayer Leverkusen late this week, hoping to end the transfer saga that started in mid-May. In the late evening on Friday night UK-time, it was reported that the Reds had upped their bid to a figure of $153 million (£113 million) — around $135 million (£100 million) base and up to around $18 million (£13 million) in add-ons. Liverpool is working on a deal for Wirtz -Credit:Getty Images understands that this is the case as negotiations continue with Leverkusen, with the player convinced on the move. Advertisement Transfer guru Fabrizio Romano recently claimed that Liverpool is "advancing" to complete the Wirtz deal in the coming days, with negotiations in the "final stages." It's claimed the player will then travel to Merseyside to complete his medical. This bid is thought to be below Bayer Leverkusen's valuation of the player, thought to be around $170 million (£126 million).
Yahoo
an hour ago
- Yahoo
France to produce drones in Ukraine, minister says
French automotive and defense companies will produce drones on Ukrainian soil, French Defense Minister Sebastien Lecornu announced on June 6, Le Monde reported. "We are going to embark on a completely unprecedented partnership where a large French car company – I won't name it because it's up to them to announce it – will join forces with a French defense SME (small to medium-sized enterprise) to equip production lines in Ukraine to be able to produce drones," Lecornu said, as quoted by the newspaper. Lecornu did not specify the types of drones to be produced. He said that, apart from Ukraine, the drones will be also provided "to our own armies… to have ongoing tactical and operational training that reflects the reality." Lecornu also said there is "no need" to send French citizens to work on the production line, since it will be set up in Ukraine, where Ukrainians "are better than us at designing drones and especially at developing the strategies that accompany them." Since the start of the full-scale invasion, Ukraine has been developing and deploying technological innovations and cutting-edge unmanned systems. Both Ukraine and Russia have increasingly relied on drone warfare, using aerial, naval, and ground-based drones for reconnaissance and combat missions. In late March, presidential advisor Alexander Kamyshin said in an interview with Radio Khartia that Ukrainian manufacturers had the capacity to produce over 5 million FPV drones per year. Read also: Ukraine war latest: Russia hits Ukraine with large-scale attack days after Operation Spiderweb; Ukraine targets Russian air bases in 'preemptive strike' We've been working hard to bring you independent, locally-sourced news from Ukraine. Consider supporting the Kyiv Independent.
Yahoo
an hour ago
- Yahoo
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)'s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment. This decline comes in contrast to a 2% rise in the broader market, suggesting that investors may be focusing on other company initiatives, such as SNY's recent partnership with Stagecoach Performing Arts to raise awareness about Type 1 diabetes. Despite the short-term drop, Sanofi (NASDAQ:SNY)'s long-term performance remains strong. Over the past five years, the company has delivered a total return of 19.59%, outpacing both the French Pharmaceuticals sector and the broader market, which saw declines of 4% and 4.5% respectively in the past year. Analysts remain optimistic about Sanofi (NASDAQ:SNY)'s future, with the current share price at €95.9 and a consensus target of €117.17, an 18.5% potential upside. The company's Projections for 2028 include revenues of €51.2 billion and earnings of €10.2 billion, supported by innovative drug development and efficient operations. While we acknowledge the potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
